Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis
Frontiers in Pharmacology · 15.05.2025 · 16
DOI: 10.3389/fphar.2025.1438318 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.05.2025. Verfasst von Mohammad Amin Karimi und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study seeks to compare the effectiveness of Semaglutide compared to Liraglutide, Dulaglutide, or Tirzepatide. Additionally, it aims to investigate the implications of transitioning from Dulaglutide or Liraglutide to Semaglutide.
Methods
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science ( ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials. Analyses were conducted using Review Manager (RevMan) version 5.4.1 and STATA 17.
Results
The meta-analysis comprised 16 studies and 5,997 patients. Semaglutide significantly reduced hemoglobin A1c (HbA1c) levels compared to Liraglutide (0.56; 95% CI: 0.19–0.94; p < 0.001). However, no significant differences were observed between Semaglutide and Liraglutide in terms of fasting blood sugar (FBS), body mass index (BMI), and weight change. In comparison to Dulaglutide, Semaglutide displayed superior efficacy in reducing HbA1c levels (3.72; 95% CI: 0.02–7.41; p = 0.05) and FBS (2.66; 95% CI: 0.26–5.07; p = 0.03). However, no significant differences were found in weight and BMI change. Tirzepatide exhibited a notable advantage over Semaglutide in reducing HbA1c levels (−0.45; 95% CI: −0.88 to −0.02; p = 0.04). However, no clear superiority was observed for weight and FBS change. Transitions from Liraglutide to Semaglutide did not significantly impact HbA1c levels. However, weight loss (2.48; 95% CI: 0.45–4.51; p = 0.02) and reduced FBS levels (10.76; 95% CI: 0.55–20; p = 0.04) were observed. Transitioning from Dulaglutide to Semaglutide did not significantly affect HbA1c levels and weight change.
Conclusion
While the precise source of heterogeneity remains elusive across most studies, analyses consistently demonstrate Semaglutide’s superior efficacy compared to Liraglutide in reducing both HbA1c levels and weight. Moreover, it presents advantages over Dulaglutide, specifically in lowering FBS levels. However, Tirzepatide surpasses Semaglutide in its efficacy for reducing HbA1c levels.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran.
- School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
- School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Student Research Committee, Faculty of Medicine, Islamic Azad University of Ardabil, Ardabil, Iran.
- School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Zitieren
APA
Karimi, M. A., Gholami Chahkand, M. S., Dadkhah, P. A., Sheikhzadeh, F., Yaghoubi, S., Esmaeilpour Moallem, F., Deyhimi, M. S., Arab Bafrani, M., Shahrokhi, M., & Nasrollahizadeh, A. (2025). Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1438318
Vancouver
Karimi MA, Gholami Chahkand MS, Dadkhah PA, Sheikhzadeh F, Yaghoubi S, Esmaeilpour Moallem F, et al. Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1438318
BibTeX
@article{Karimi2025,
author = {Karimi, Mohammad Amin and Gholami Chahkand, Mohammad Sadra and Dadkhah, Parisa Alsadat and Sheikhzadeh, Farzad and Yaghoubi, Shayan and Esmaeilpour Moallem, Fatemeh and Deyhimi, Mitra Sadat and Arab Bafrani, Melika and Shahrokhi, Mehregan and Nasrollahizadeh, Amir},
title = {Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1438318}
}
EUVIMED